Background and objective: Co-morbidities are frequent among patients with interstitial lung diseases (ILD). The objective of this study was to investigate their impact on mortality. Methods: We used the Danish National Patient Registry (DNPR) to identify all patients with a first-time diagnosis of ILD between 1998 and 2010. Patients with ILD were matched 1:4 with controls from the background population. The burden of co-morbidity was assessed using the Deyo-Charlson co-morbidity score (DCcs). Mortality risks were assessed using Kaplan-Meier survival curves, and hazard rate ratios (HRR) for death were estimated using Cox proportional hazards regression models. Results: We identified 10 629 patients with ILD with a corresponding incidence estimate of ILD in Denmark of 17.6 per 100 000 inhabitants (95% CI: 16.5-18.7). Mean age was 72 years and 45.6% of the patients were females. Co-morbidity (DCcs ≥ 1) was present in 30% of the ILD patients and 12% of the controls (P < 0.001).
INTRODUCTION
Interstitial lung diseases (ILD) represent a heterogeneous group of lung diseases. Survival is highly dependent on the subtype of ILD, 1 but the course of disease is unpredictable. 2 The most common of the ILD, idiopathic pulmonary fibrosis (IPF), has a dismal prognosis, although the recent improvements in the therapeutic options decrease disease progression and prolong survival. 3, 4 Age and smoking are known risk factors for IPF and predispose to multiple pulmonary and extra-pulmonary co-morbidities. Ischaemic heart disease and diabetes are common co-morbidities in IPF, [5] [6] [7] and may contribute significantly to mortality. This pattern is the same as in larger chronic diseases, for example, chronic obstructive pulmonary disease (COPD) and lung cancer. 8, 9 Previous studies of co-morbidities in ILD have focused mainly on IPF, but co-morbidities in other ILD are seeing an increased focus. Their presence often excludes patients from participation in clinical trials and guidelines on clinical management rarely address co-morbidities. The identification of important comorbidities in ILD may point to interventions with the potential of reducing mortality. The Deyo-Charlson comorbidity score (DCcs) is widely used as a tool to measure co-morbidity and to evaluate their impact on mortality. [10] [11] [12] The objective of this study was to determine the impact of co-morbidities on mortality in ILD by use of the DCcs.
METHODS

Design
The study is a matched cohort study using prospectively collected data from population-based medical databases.
Data sources
The Danish National Patient Registry (DNPR) 13 contains information about Central Person Registry (CPR) number, dates of hospital contacts, diagnostic and surgical procedure codes and discharge diagnoses. The International Classification of Diseases, 10th edition (ICD-10) has been used for discharge diagnoses coding since 1994. The DNPR was used as the source of information about all hospital contacts.
The Danish Civil Registration System (CRS) 14 provided information about date of birth, place of residence and vital status. The CPR number assigned to all Danish residents enables individual level linkage across all different registries. The system ensures complete follow-up with respect to mortality.
Statistics Denmark provided information about cohabitation status, marital status, social factors, employment, education, income and pensions.
Study population
We identified all patients who had been assigned a first-time diagnosis of ILD between 1 January 1998 and 31 December 2009 in the DNPR. We used the ICD-10 diagnostic code DJ84 for the identification of patients with ILD.
The ILD patients were matched 1:4 for age, gender, marital status and area of residence with randomly selected controls from the CRS. We selected control subjects who lived in the same part of the country and had the same marital status as the patients in order to minimize social status bias.
The index date was defined as the date when the patient was assigned a diagnosis of ILD for the first time. Matched controls without ILD were assigned the same index date as the ILD patient.
Identification of co-morbidities
We obtained a complete hospitalization history for the ILD patients and the matched controls without ILD based on all inpatient and outpatient diagnoses recorded in the DNPR 3 years before and 3 years after the ILD diagnosis. To measure co-morbidity, we computed the DCcs 11, 12 for each patient using the ICD-10 diagnostic codes listed in Table S1 (Supplementary Information). The ILD diagnosis was not included in the DCcs calculation.
The ICD-10 diagnostic codes obtained from the DNPR were classified into main disease groups according to the ICD-10 disease chapters. 15 The study was approved by the Danish Data Protection Agency.
Statistical analysis
A conditional logit model was used to yield outputs expressed as odds ratios (OR) with 95% CI. First, a conditional logit was estimated for the main diagnoses. Afterwards, a conditional logit was estimated for diagnoses occurring in ≥1% of patients or controls. Diagnostic codes were grouped manually. A Kaplan-Meier model was used to estimate the survival distribution function using the date of the ILD diagnosis as the index date. A Cox proportional hazards model was used to estimate the hazard rate ratio (HRR) for death. A significance level of 0.05 was assumed for all tests. Statistical analysis was performed using SAS 9.1.3 (SAS, Inc., Cary, NC, USA).
RESULTS
Demography
A total of 10 629 ILD patients and 42 758 matched controls were identified. The corresponding incidence of ILD in Denmark is 17.6 per 100 000 inhabitants per year (95% CI: 16.5-18.7) (5.5 million inhabitants (2009)). Mean age in the ILD group was 72 years and 45.6% of the patients were females. Age and gender distribution was well balanced between the ILD group and the matched control group (Table 1 ). An incidence peak was observed in the age group 70-79 years (28%). The male overweight was seen for all age groups except the 20-29 and the above 80 groups, but the male dominance increased with increasing age.
The distribution of J84 subdiagnoses was J84.1 (other ILD with fibrosis) 32.2%, J84.8 (other ILD) 9.1%, J84.9 (ILD not otherwise specified) 57.7% and remaining J84 subdiagnoses 1%.
Co-morbidity patterns and survival
The distribution of co-morbidities identified within 3 years before and 3 years after the ILD diagnosis is shown in Table S2 (Supplementary Information). Among patients with ILD, the most frequent comorbidities before the ILD diagnosis were diseases of the respiratory system (24%) and the circulatory system (21%). In the control group, the most frequent comorbidities were diseases of the circulatory system (12%) and diseases of the musculoskeletal and connective tissue system (11%). After the ILD diagnosis, the most common co-morbidities in the ILD group were unchanged. The distribution of non-ILD respiratory diagnoses before and after the ILD diagnosis is shown in Table S3 (Supplementary Information).
Connective tissue diseases (CTD) were registered in 4.9% of ILD patients (525/10 629) versus 0.7% of controls (301/42 758). The diagnoses considered were rheumatoid arthritis (RA) (289 patients in the ILD group vs 196 individuals in the control group), systemic lupus erythematosus (58 vs 4), dermatopolymyositis (28 vs 4), systemic sclerosis (47 vs 3) and Sjögren's disease (103 vs 94).
Diabetes, which was the major component of endocrine diseases, occurred twice as frequently among ILD patients before (6% vs 3.3%) and after the ILD diagnosis (9% vs 4.6%).
The DCcs was zero (no registered co-morbidity was included in the score) in 70% of the ILD patients and 88% of the controls. Any DCcs of 1 or higher was more frequent in the ILD group ( Table 2) .
The 5-year survival was 56.0% (95% CI: 54.6-56.6) among patients with ILD versus 84.0% (95% CI: 83.7-84.4) among controls. Decreasing survival with increasing DCcs was seen in both groups (Table 3) . The observed survival difference between ILD patients and controls was highest in the strata with DCcs 0 (61% vs 87%). Kaplan-Meier survival curves for all ILD patients and controls are shown in Figure 1 . Survival curves for each level of DCcs are shown in Figure 2 .
The 5-year survival among ILD patients was 52% for males (95% CI: 51-53) and 61% (95% CI: 59-62) for females (P < 0.001). HRR for death was significantly increased among males in the ILD group compared with male controls (HRR: 3.82 (95% CI: 3.63-4.02)). The same pattern was seen among females with ILD compared with female controls (HRR: 3.85 (95% CI: 3.62-4.09)).
The risk of death among patients with ILD was increased for all age groups, but the risk was higher among younger adults, with a peak HRR of 41.5 (95% CI: 9.7-177.1) in the age group 20-29 years (Table 4 ).
DISCUSSION
This study shows a higher burden of co-morbidities in patients with ILD than in age-and gender-matched controls without ILD, and the presence of comorbidities affected survival significantly.
The 5-year survival was significantly lower in ILD patients than in matched controls (56% vs 84%, P < 0.001). These findings are in agreement with a previous study of ILD in Denmark from our group showing an overall 5-year survival of 57% (34% in IPF, 74% in idiopathic non-specific interstitial pneumonia (NSIP) and 93% in hypersensitivity pneumonitis).
1 Very few overall estimates of incidence and prevalence of ILD have been reported. In this study, we attempted to overcome the limitations of small ILD cohorts from referral centres by reporting nationwide registry data. The corresponding incidence estimate of ILD is four times higher than a previous estimate based on single centre data from our institution. 1 The higher estimate is probably the most accurate, but comes at the price of loss of clinical information of HRCT patterns, disease severity and ILD subtyping. Even though the registry data may include more patients with milder disease, who are not referred to tertiary centres, the excess mortality among patients with ILD is striking.
The majority of ILD patients were males, and the male predominance increased with increasing age. The main exception was the female predominance in the above 80 age group. This may be explained by the male predominance and high mortality in IPF, which is among the most common ILD in the above 60 age group. The longer life expectancy for females also contributes to the observed gender distribution. The female predominance among patients with CTDassociated ILD (CTD-ILD) may account for the higher proportion of females among younger ILD patients.
The frequency of respiratory infections increased significantly after the ILD diagnosis. Increased risk of infection because of chronic lung disease is obvious, but the immunosuppressive therapies used for some ILD may also contribute. A recent study of hospital admissions for acute respiratory worsening in patients with fibrotic lung diseases 16 showed that in-hospital mortality was high, but no difference was observed between patients with IPF and patients with non-IPF fibrotic lung disease.
The frequency of COPD may be overestimated from registry data because of the similarities in population characteristics and symptoms that may account for invalid diagnoses. A previous study of patients with pulmonary fibrosis reported that almost half of the participants had been given an incorrect initial diagnosis of respiratory disease other than ILD. 17 However, the presence of combined fibrosis and emphysema may contribute. 18 Regardless of the specific cause, the distribution of respiratory diagnoses between the ILD group and the controls reflects a very high burden of respiratory morbidity causing hospital contacts among patients with ILD. This is consistent with previous findings in a large registry-based study focusing on IPF. 19 Respiratory malignancies were more frequent among ILD patients. Fibrotic lung disease in itself increases the risk of cancer, but this finding also reflects that some ILD are smoking-related, most notable are desquamative interstitial pneumonia and respiratory bronchiolitis-ILD. Although not classified as smokingrelated ILD, the majority of IPF patients are smokers or ex-smokers, 20 and smoking is also a risk factor for RAassociated ILD (RA-ILD). 21 The risk of lung cancer is increased, especially in IPF patients. 22 Therapy-related toxicities occur especially in IPF, [23] [24] [25] but less in other ILD and are associated with high mortality in IPF. 26 This study shows that cardiovascular diseases are more frequent among patients with ILD. Previous population-based studies have showed increased frequency of cardiovascular disease and diabetes in IPF compared with matched controls, 27, 28 but no previous data are available for non-IPF ILD. However, it is well known that patients with RA are at increased risk of ischaemic heart disease, 29, 30 and patients with RA-ILD constitute an important subgroup of non-IPF ILD patients at risk of cardiovascular disease. Standard follow-up for RA includes the identification and treatment of risk factors according to international guidelines. 31 Diabetes occurred more frequently among ILD patients before the ILD diagnosis, suggesting that diabetes may not only be a side effect of ILD therapy but also play a role in initiation and progression of fibrosis by hyperglycaemia-associated pulmonary inflammation. 32, 33 Based on our registry data, CTD-ILD constitutes 4.6% of the total ILD cases, and CTD are much more frequent among ILD patients than among controls. In a previous study from our centre, CTD-ILD constituted 14% of an ILD cohort, and was second only to IPF. 1 Similar findings have been reported from other cohort studies of ILD. 34, 35 RA-ILD was the largest subgroup of the CTD-ILD in this study which reflects that RA affects 1% of the population. 36 Scleroderma and poly-and dermatomyositis are rare in the general population, but a large proportion of these patients have ILD, which is the cause of severe morbidity and excess mortality. 37 No difference was seen in the frequency of diagnoses of psychiatric diseases in the DNPR between ILD patients and controls. However, the prevalence of depression and anxiety is likely to be underreported in hospital registries. These conditions are often diagnosed and treated in general practice, and the assigned diagnoses from general practice are not registered in the DNPR. Holland et al. reported a high frequency of anxiety and depression among patients with ILD 38 and showed that the number of co-morbidities contributed independently to depression while measures of disease severity and type of ILD were not related to either anxiety or depression.
The strength of our study is its population-based design, the prospective nature of the data collection in the national registries and the completeness of followup with respect to mortality.
The validity of the ICD-10 diagnostic codes for ILD in general is likely to be high because these rare diagnoses are assigned mainly by pulmonologists. A previous study reported a high positive predictive value of DNPR diagnoses for conditions included in the DCcs, 39 which supports the validity of the co-morbidity assessment.
The main limitation of our study was the inability to distinguish between IPF and other ILD based on registry data. The use of the ICD-10 code for IPF (DJ841A) was inconsistent during the study period, and the majority of patients were assigned the unspecific codes J84.8 and J84.9 (66.8% of the patients). Therefore, we chose not to include specific ICD-10 codes for ILD subtypes. The same conclusion about the validity of ILD subtype diagnoses was reached in a recent study from Finland. 40 Although ILD are a diverse group of disorders, similarities in disease patterns and prognostic factors exist across ILD subtypes. As an example, the ILD-gender age physiology (GAP) accurately predicts mortality in major chronic ILD subtypes at all stages of disease. 41 Furthermore, the diagnostic process in ILD is challenging and often difficult. A recent study reported good agreement between multidisciplinary teams for a diagnosis of IPF, but lower agreement for NSIP and hypersensitivity pneumonitis. 42 With these considerations in mind, this study of a large population-based cohort of ILD patients contributes with reliable information about demographics, patterns of co-morbidity and survival, although limited by lack of ILD subtypes and disease severity.
In conclusion, this study is the first population-based cohort study of patients with ILD and provides an incidence estimate for ILD of 17.6 per 100 000 inhabitants per year. Overall mortality was significantly increased among patients with ILD compared with age-and gender-matched controls. Increasing DCcs corresponded to increased mortality among ILD patients as well as controls. However, the difference in mortality decreased with increasing DCcs suggesting that a high burden of co-morbidity tends to close the mortality gap, although the risk of death remained significantly increased for ILD patients regardless of age group or level of co-morbidities.
Table S1
List of ICD-10 diagnostic codes used for the assessment of the Deyo-Charlson co-morbidity score. Diagnostic codes for interstitial lung diseases were excluded. Table S2 Distribution of co-morbidities among interstitial lung disease (ILD) patients and controls before and after the diagnosis of ILD according to ICD-10 disease chapters. Table S3 Other respiratory diagnosis assigned before and after the interstitial lung disease diagnosis.
